GlassScriptPhysician profile
Matthew S Porter
NPI 1649658618
$7,251.57
in general payments reported to CMS, 2019-2025
9 companies · $698 in 2025
The $698 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $531 · 2020: $573 · 2021: $402 · 2022: $1,393 · 2023: $928 · 2024: $2,725 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,900 · Food and Beverage: $1,452.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,900.00 |
| Food and Beverage | $1,451.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $4,900.96 | 2019-2025 | Idose, Gts100-Glaukos Istent Trabecular Micro-Bypass Stent System, Iaccess Precision Blade |
| Alcon Vision LLC | $888.59 | 2019-2025 | Hydrus Microstent, Centurion, Clareon |
| Sight Sciences, INC. | $446.93 | 2021-2024 | Omni Surgical System |
| Aerie Pharmaceuticals, INC. | $350.53 | 2019-2021 | |
| Allergan, INC. | $265.32 | 2019-2020 | |
| Ivantis, INC | $191.14 | 2019-2020 | |
| New World Medical,INC. | $145.45 | 2023 | |
| Kala Pharmaceuticals, INC. | $33.51 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $29.14 | 2019-2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Porter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.